Lexicon Pharmaceuticals (LXRX) Interest Expenses (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Interest Expenses data on file, last reported at $4.3 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 44.88% year-over-year to $4.3 million in Q1 2026; TTM through Mar 2026 was $4.3 million, a 72.3% decrease from a year earlier, with the FY2025 full-year figure at $11.6 million, down 97.23% from the prior year.
• Interest Expenses for Q1 2026 stood at $4.3 million, up from $2.0 million in the prior quarter.
• Over the last five years, Interest Expenses for LXRX reached as high as $10.3 million in Q3 2023 and fell as low as $110000.0 in Q1 2022.
• Historically, Interest Expenses has averaged $4.0 million across 5 years, with a median of $4.3 million in 2026.
• Across the five-year window, Interest Expenses surged 1555.45% in 2023 and sank 69.29% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $1.0 million in 2022, then soared by 437.8% to $5.4 million in 2023, then rose by 6.71% to $5.8 million in 2024, then slumped by 64.89% to $2.0 million in 2025, then soared by 111.72% to $4.3 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $4.3 million in Q1 2026, $2.0 million in Q4 2025, and $4.5 million in Q3 2025.